Trial Profile
A Multi-Center Phase III Study to Evaluate MALG, a Novel Malathion 0.05% Formulation, for the Control of Head Lice in Pediatric and Adult Subjects With Pediculosis Capitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Dec 2013
Price :
$35
*
At a glance
- Drugs Malathion (Primary) ; Permethrin
- Indications Pediculosis
- Focus Registrational; Therapeutic Use
- Sponsors Taro Pharmaceuticals USA
- 31 Dec 2013 New trial record